Growth Hormone Deficiency Therapeutics Pipeline Analysis - Designation and Developments

Growth hormone deficiency (GHD) therapeutics pipeline is predicted to increase in future mainly due to the increasing prevalence of the disease, globally.

The rising affordability of the drugs and increasing geriatric population also serve as major factors leading to growth of the pipeline. According to the Human Growth Foundation, it is estimated that growth hormone deficiency occurs in children between 1 to 4,000 to 1 to 10,000, in the U.S. There are more than 50,000 adults associated with growth hormone deficiency and around 6,000 new cases are being reported per year.

Explore Report at: https://www.psmarketresearch.com/market-analysis/growth-hormone-deficiency-therapeutics-pipeline-analysis

Growth hormone is a major body system metabolic hormone that controls lipid, protein and carbohydrate homeostasis. The principal form of growth hormone is around 22 kD and contains 191 amino acids, known as somatotrope. This hormone is produced by growth hormone cells known as somatotropes located in adenohypophysis of pituitary gland. Growth hormone deficiency is classified into four categories as pituitary or classic GHD, hypothalamic GHD, functional growth hormone deficiency and idiopathic GHD. In case of pituitary GHD, there is an abnormality in brain, due to which there is an incapacity to produce growth hormone. Hypothalamic GHD occurs when there is failure of hypothalamic function of transmitting neurocrine messaging hormone, which directs the pituitary gland to produce growth hormone. Functional GHD occurs when other metabolic hormone fails to secrete or impaired metabolic function due to various unknown etiologies. Idiopathic GHD occurs due to unknown causes. There are various psychological symptoms that occur in growth hormone deficiency such as depression, lack of concentration, emotional distress and poor memory. The disease can also lead to increased fat mass and extra cellular fluid volume, diminished muscle strength and stamina, lethargy and depression.

Request for Table of Content at: https://www.psmarketresearch.com/market-analysis/growth-hormone-deficiency-therapeutics-pipeline-analysis/toc-sample

Some of the companies having a pipeline of growth hormone deficiency therapeutic pipeline analysis include Merck Serono, Pfizer, Inc., Novo Nordisk, F. Hoffman-La Roche AG, Eli lilly and Company, Ferring pharmaceuticals, Inc. LG Life Sciences Pvt. Ltd., Sandoz Internatinal, Teva Pharmaceutical industries, OPKO Health, Inc., AnkeBio Co., Ltd.


Contact Details

Company Name: P&S Market Research
Issued By: Vijay
Phone: +1-888-778-7886
Address: 347, 5th Ave. #1402 New York City, NY - 10016
City: New York
State: New York
Zip: NY 10016
Country: United States
Website: Visit the website

Keywords : Growth Hormone Deficiency Therapeutics Pipeline Analysis, Growth Hormone Deficiency Therapeutics Pipeline, Growth Hormone Deficiency Therapeutics Pipeline Report, Growth Hormone Deficiency Therapeutics Pipeline Analysis Research,

by Vijay (few years ago!)

Latest Press Releases

The Mad Hatter Now Offer a Full Line of Hearth Products and Full Line of Grills

Diabetes Insulin Delivery Pens Market Research Report 2018

Dr Kapadia Provides Tips to Patients Interested in Hair Transplant Procedures

love vashikaran specialist

Solar Blanket Sales Market Report 2018

Spring Bottled Water Market Insights, Forecast to 2025

Biochemical Incubator Sales Market Report 2018

Quinine Sulphate Sales Market Report 2018

Automotive Chassisc System Market Insights, Forecast to 2025

2,6-Dicarboxypyridine market size in key regions like North America, Europe, Asia Pacific an..

Remove this press release ?

Due to extra work required to remove the press-releases we have started charging $1.99 for press release removal.

Your press release will be removed in 24 hours, once the payment has been received.

Search Press Release
e.g. Business, Computer, etc.